The Virginia Commonwealth University (VCU) Minority-Based Community Clinical Oncology Program (MBCCOP) improves access to state-of-the-art cancer treatment and cancer prevention and control research trials to the urban and rural communities of Richmond and Southside Virginia. Over forty percent of new cancer cases seen in the VCU MBCCOP are from minority populations, primarily African-Americans. Organizational and operational plans, which provide the structure for the effective implementation of multidisciplinary research, are presented. This application emphasizes the unique urban and rural population available to the VCU MBCCOP, the history of extensive participation by primary health care providers and specialists, in particular, surgeons, gynecologic oncologists, and radiation oncologists in clinical research at VCU, and VCU initiatives in cancer outreach conducted at rural MBCCOP sites. Currently, the VCU MBCCOP has affiliations with four CCOP research bases: NSABP, CALGB, GOG, and NCCTG. It also participates in trials available through the Cancer Trials Support Unit (CTSU). The application describes the working relationships with the research bases and the focus of the VCU MBCCOP to accrue significant numbers of minority participants to both treatment and cancer prevention and control clinical trials. Working relationships of the VCU MBCCOP investigators, clinical research teams, and support services and personnel are described. The role of the VCU MBCCOP in promoting quality cancer care through treatment and cancer prevention and control studies to traditionally underserved segments of the population, the urban and rural minorities, as well as future plans are discussed.
The enrollment of minority participants in clinical trials provides a broader knowledge of the impact of new cancer treatments on the entire population. In addition, inclusion of minority participants in cancer prevention and control trials enables an understanding of potential differences between racial and ethnic populations in the effectiveness of the interventions.
|Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58|
|Uy, Geoffrey L; Mandrekar, Sumithra J; Laumann, Kristina et al. (2017) A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv 1:331-340|
|Ports, Katie A; Ayers, Antoinette; Crocker, Wayne et al. (2015) Community perceptions and utilization of a consumer health center. J Med Libr Assoc 103:35-9|
|Rafie, Carlin; Ayers, Antoinette; Cadet, Debbie et al. (2015) Reaching Hard to Reach Populations with Hard to Communicate Messages: Efficacy of a Breast Health Research Champion Training Program. J Cancer Educ 30:599-606|
|Mosavel, Maghboeba; Rafie, Carlin; Cadet, Debbie L et al. (2012) Opportunities to reduce cancer barriers: community town halls and provider focus groups. J Cancer Educ 27:641-8|
|Bertagnolli, Monica M; Redston, Mark; Compton, Carolyn C et al. (2011) Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 29:3153-62|
|Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2008) Wilms'tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26:4595-602|
|Silverman, Lewis R; McKenzie, David R; Peterson, Bercedis L et al. (2006) Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-903|
|Lamont, Elizabeth B; Herndon 2nd, James E; Weeks, Jane C et al. (2006) Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). J Natl Cancer Inst 98:1335-8|
|Halabi, Susan; Vogelzang, Nicholas J; Ou, San-San et al. (2006) Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 176:81-6|
Showing the most recent 10 out of 22 publications